An HIV Vaccine: The World's best long-term hope for ending AIDS.

Who We Are

We are the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS. Learn more >

What We Do

Our sites conduct all phases of clinical trials - from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. Learn more >

Get Involved

Worldwide, thousands of people have participated in HIV vaccine trials.  Volunteers are the heroes of vaccine development. Learn more >

Dr. Larry Corey Principal Investigator, HVTN

MAY 18 IS NATIONAL HIV VACCINE AWARENESS DAY

A message from Dr. Larry Corey, Principal Investigator, HVTN

HIV Vaccine Awareness Day 2015 marks an important milestone in our field with an unprecedented return of energy and optimism.  Several studies evaluating new vaccine regimens are being initiated in sub-Saharan Africa, as well as parts of the US and South America.

The long awaited P5 program has begun, as has the program involving Johnson and Johnson laboratory, Janssen.  There is both enthusiasm and optimism that the milestones for advancement of these new vaccine products will occur and efficacy evaluation will be initiated next year. Read more >


(Top Left) Mr. Antelmo Haule scientist - Main laboratory. (Top Right) Community engagement activities in the community. (Bottom Left) NIMR-Mbeya Medical Research Center (the new CRS). (Bottom Right) CAB members at World AIDS day 2013.

MBEYA CLINICAL RESEARCH SITE PROFILE 

A Small HIV Intervention  Programme becomes a Government Clinical Trial Centre

The Mbeya region in Tanzania is a remote, rural area that encompasses two major highways and is adjacent to two international borders. In the late 1980s, the HIV epidemic rapidly expanded in the Mbeya region, fueled by these unique geographic features and exacerbated by a lack of trained health staff, shortage of medicine, and a poor healthcare infrastructure.  Read More.


SCIENCE FEATURE STORY

HIV is one of the most changeable viruses discovered to date

Antibodies that are able to adhere to the outer shell of HIV can inactivate the virus, and potentially stop infection before it starts. However, HIV is one of the most changeable viruses discovered to date, and the strains in circulation vary widely. An ideal vaccine against HIV would produce antibodies that could inactivate all HIV strains, but the reality is that antibodies against one strain usually don’t work against others. Read more >

Scholar Awards

We support the next generation of HIV researchers with structured mentoring, projects, training, and networking opportunities. Learn more >


Get the Right HIV Test

Getting the right test will prevent an incorrect diagnosis of HIV.  Your study site or VISP Testing Service can provide the right test.  Visit our frequently asked questions for more information.

TWITTER FEED


LATEST NEWS

HIV Vaccine Trials Network

Fred Hutchinson Cancer Research Center